Skip to content
Trial Eligibility
Menu

Extracellular RNA Biomarkers of Myotonic Dystrophy

NCT05020002

This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Myotonic Dystrophy

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
5 years and older
Sex
All
Healthy volunteers
Accepted
Sponsor
Massachusetts General Hospital
Last updated on ClinicalTrials.gov
November 24, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Massachusetts · 2

  • Beth Israel Deaconess Medical Center · Boston, MA
  • Massachusetts General Hospital · Boston, MA

Texas · 1

  • University of Texas Southwestern · Dallas, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.